Nitto Denko just printed its Q2 2027 scorecard and the stock closed at ¥3,422, leaving the past week down about 7%. The reaction feels cautious even though the latest quarter showed solid earnings power, with basic earnings per share at roughly ¥64.66 on revenue of about ¥286.7b.
For traders staring at the red on the screen, the short-term move dominates the story. Long-term holders will focus more on the trailing twelve month earnings of roughly ¥141.1b and a P/E of 16.1x that sits below peer levels yet above the broader chemicals sector.
Like the earnings profile at Nitto Denko but uneasy about the recent pullback and mixed valuation signals? Check out our screener of quality shares with steadier setups in the list of solid balance sheet and fundamentals stocks (23 results).
Q2 2027 Earnings Summary
- Revenue (Q2 2027 vs. Q2 2026): ¥286,691m vs. ¥267,377m (up about 7%)
- Net Income (Excl. Extra Items, Q2 2027 vs. Q2 2026): ¥42,630m vs. ¥37,623m (up about 13%)
- Basic EPS (Q2 2027 vs. Q2 2026): ¥64.66 vs. ¥55.72 (up about 16%)
- Trailing 12-Month Net Income (Excl. Extra Items, Q2 2027 vs. Q2 2026): ¥141,074m vs. ¥126,188m (up about 12%)
Earnings keep climbing while Nitto Denko trades below estimated value. Ask Charlie what makes Nitto Denko’s undervaluation stand out.
Nitto Denko’s CapEx Ambitions Meet Early Proof Points
Bulls argue that Nitto Denko is mid pivot toward a richer product mix and higher capital productivity. The ambition is clear.
"The main factor that needs to go right is successful execution of the expanded CapEx program across semiconductor, Human Life and display materials, so that the planned capacity and product launches translate into the projected profit mix by 2028 and 2030."
Q2 results show earnings and trailing net income both ahead of the prior year, which supports the idea that current projects are not dragging profitability. Recent moves in Human Life, including the Hemogenyx CAR mRNA partnership, plus the buyback aimed at lifting ROE, are tangible milestones toward that capital allocation story.
The price and this Narrative do not agree. → Uncover what this Narrative says Nitto Denko is actually worth.
Nitto Denko Bears Still Waiting For Margin Cracks
Concern has been that Nitto Denko’s pivot would stall while legacy display products soaked up capital without adequate pricing power.
"While management is expanding capacity for electrical release tape and OCA at the Toyohashi plant to 1.7 times the FY25 level, intensifying cost competition in mature display markets could absorb this new supply at weaker pricing, limiting the contribution to revenue growth and compressing net margins."
Latest figures show revenue and net income both ahead of last year, so the feared squeeze is not evident yet. The share price, down 7% over the week and slightly over the month, signals that investors are still unconvinced this capacity build will earn through.
Hunt For Quiet Mispricings
Nitto Denko just showed how a reasonably solid earnings profile can still sit alongside a hesitant share price. The real opportunity could be spotting shares that look mispriced before consensus recognises emerging business strengths.
- Company 1 - 32% below our estimate - lets merchants route transactions across cards, wallets and bank debits without rebuilding checkout flows.
- Company 2 - 49% below our estimate - enables bottle producers to reconfigure molding systems so lines can accommodate new container formats.
- Company 3 - 35% below our estimate - secures long duration construction and infrastructure contracts that integrate maintenance and real estate monetisation.
Three companies from the same screener. Open the full list of 15 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com